The paragraphs presented above incorporate changes as indicated by the marked-up versions below.

The paragraph bridging pages 5 and 6:

Figure 2 illustrates the transfection of cells with mouse serum albumin (MSA)-Myc fusion constructs and successful expression of the fusion protein, as well as binding of MSA and Myc antibodies to MSA-Myc fusion proteins depending on the location of the heterologous sequence in the MSA protein. The Myc epitope sequences in the figure is represented by SEQ ID NO: 2.

In the claims:

Please cancel claims 1-27, 34-53, and 89-92 without prejudice.

For the convenience of the Examiner, all elected claims (28-33 and 54-88), whether or not amended, are presented below.

28. (**Amended**) A nucleic acid encoding a chimeric polypeptide comprising serum albumin protein (SA) having a biologically active peptide sequence inserted therein, wherein the chimeric polypeptide exhibits increased biological activity relative to said peptide sequence itself, wherein said peptide sequence is heterologous to said serum albumin protein.

29. (**Reiterated**) A delivery vector comprising the nucleic acid of claim 28, 54, or 55.

30. (**Reiterated**) The delivery vector of claim 29, wherein said delivery vector comprises a virus or retrovirus.

31. (**Reiterated**) The delivery vector of claim 30, wherein said virus or retrovirus is selected from adenoviruses, adeno-associated viruses, herpes simplex viruses, human immunodeficiency viruses, or vaccinia viruses.

32. (**Reiterated**) Transfected cells comprising target cells which have been exposed to the delivery vector of claim 29.